Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Ovarian Cancer
  •  Prostate Cancer
  •  Urological Cancers
  •  Gynecological Cancers
  •  Haemato-Oncology
  •  Lung Cancers
  •  Chemoprevention
  •  Immunology

Abstract

Citation: Clin Oncol. 2019;4(1):1630.DOI: 10.25107/2474-1663.1630

Prostate Cancer: A Continuous Evolutionary Search for Molecular Therapy Targets

Marcia Mashianoke Lekganyane and Lesetja Raymond Motadi

Department of Biochemistry, University of Johannesburg, Auckland Park, Johannesburg, 2050, South Africa

*Correspondance to: Lesetja Raymond Motadi 

 PDF  Full Text Mini Review | Open Access

Abstract:

Prostate Cancer (PCa) is the most frequently diagnosed carcinoma in males and one of the leading causes of death in men around the globe [1]. Recent studies estimate that over a million males are diagnosed with prostate cancer on an annual basis, with approximately 0.3 million prostate cancerrelated deaths per annum. Development of Castration-Resistant Prostate Cancer (CRPC) culminates from over-expression of the Androgen Receptor (AR) gene; mostly through amplification of the AR gene, AR gene mutations and elevated synthesis of androgens in prostate cancer tumors. Advanced CRPC eventually develops to metastatic Castration-Resistant Prostate Cancer (mCRPC) in all patients. On the other hand, TP53 gene has the highest frequency of mutations across all variations of human cancer, with well over 50% of alterations found on various regions of the protein. Missense mutations of p53 frequently result in the loss of wild-type p53 (wtp53) which plays a very vital role in tumour suppression. In prostate cancer, Tp53 is one of the most common mutated or in activated protein which results in cancer development and progression. This review aims to look at progress made to date on both Tp53 targeted therapy in relation to all existing therapy both in clinical trials and those that still at initial phases.

Keywords:

Prostate cancer; Cisplatin; RGX-104; p53; Nutlin-3

Cite the Article:

Lekganyane MM, Motadi LR. Prostate Cancer: A Continuous Evolutionary Search for Molecular Therapy Targets. Clin Oncol. 2019; 4: 1630.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Bioinformatics-Based Identification of CCNB2 as a Key Gene in the Progression of Chromophobe Cell Carcinoma of Kidney
 Abstract  PDF  Full Text
Cardiovascular Screening and Prevention in Female Breast Cancer Patients Receiving Radiotherapy
 Abstract  PDF  Full Text
View More...